Givaudan SA (GIVN.SW): Deep Dive Research Report

Basic Materials | SIX Swiss Exchange | Report date: 8 October 2026

Reporting period anchor. Givaudan's financial year ends on 31 December. It publishes full-year results in late January, half-year results in late July, and sales-only updates after the first quarter (April) and nine months (October). The latest full results are the 2026 half-year, released 23 July 2026. The nine-month 2026 sales update is scheduled for 13 October 2026, five days after this report. The company's own H1 2026 release lists that date under "next events", so the absence of 9M 2026 data is confirmed, not search lag. The six results events used throughout are: Q1 2025 sales (April 2025), H1 2025 results and call (22 July 2025), 9M 2025 sales (October 2025), FY2025 results and call (29 January 2026), Q1 2026 sales (April 2026) and H1 2026 results and call (23 July 2026). The 27 August 2026 Summer Investor Conference is used as a supplementary strategy event.

1. What the Company Does

Givaudan invents and manufactures the smell of things and the taste of things, then sells them in bulk to the companies whose brands are on the shelf. It does not make a single consumer product. When a shampoo smells of green apple, a detergent leaves "fresh linen" on a towel, a luxury perfume opens with bergamot, a protein shake does not taste chalky or a plant-based burger tastes like grilled beef, there is a good chance a Givaudan perfumer or flavourist designed the formula. A Givaudan plant mixed it, and a drum or tanker of the concentrate went to the brand owner's factory. The consumer never sees the name. The brand owner pays for a few kilograms of concentrate per tonne of finished product, a small share of what the product costs to make that decides much of whether a consumer buys it a second time.

Two divisions do this. Fragrance & Beauty creates fragrances for perfumes, personal care, household cleaning and laundry. It also makes the aroma molecules those fragrances are built from, and active ingredients for skin care. Taste & Wellbeing creates flavours, taste-modifying systems (sugar, salt and fat reduction, masking off-notes in proteins and vitamins), natural colours and plant-based functional ingredients for food, beverage and nutrition companies.

How it got here. The business was founded as a perfumery company in Zurich in 1895 by the brothers Léon and Xavier Givaudan, and moved to Geneva in 1898, where it built the Vernier factory that is still its home. Roche bought Givaudan in 1963 and the French perfumery house Roure, founded in Grasse in 1820, a year later. In 1991 the two were merged into Givaudan-Roure, and US flavour house Fritzsche, Dodge & Olcott was folded in. The Roche years also carry the darkest chapter: the 1976 Seveso dioxin release came from ICMESA, a Givaudan subsidiary, and it shaped European chemical-safety law (the Seveso Directives). In 2000 Roche spun the business off as an independent listed company on the Swiss exchange. Three deals then turned a fragrance house with a flavour arm into the sector's largest player:

• 2002, FIS: Nestlé's flavour business. Nestlé took a 10% stake as part of the price.
• 2007, Quest International: bought from ICI, consolidating one of the remaining large independent houses.
• 2014-2025, a long programme of bolt-ons that widened the definition of what Givaudan sells beyond flavour and fragrance. It moved into cosmetic actives (Induchem, Soliance), natural plant extracts (Naturex, 2018), natural colours (DDW, 2021; b.kolor, 2025) and smaller regional fragrance houses aimed at local customers (Custom Essence, Drom, Belle Aire Creations, Vollmens). The 2026 agreement to buy a majority of Eurofragance continues the pattern (Section 7).

The company now describes itself as operating in an "expanded market" of flavour, taste, functional ingredients, fragrance and beauty. It has more than 17,500 employees across 167 locations, including 77 production sites, and it says about 10% of turnover goes into research and innovation.

Leadership continuity, then a break. Gilles Andrier ran the company as CEO for 20 years, out of more than 30 at Givaudan. In that time it grew from 5,900 to 16,900 employees and from CHF 2.7 billion to CHF 7.4 billion of sales (Givaudan leadership-change release, 2025). On 1 March 2026 he handed over to Christian Stammkoetter, an outsider from Danone, and at the March 2026 AGM he became Chairman. Stammkoetter's background and the governance meaning of this arrangement belong to Sections 7 and 10.

The value proposition. Givaudan solves a problem consumer-goods companies cannot solve cheaply themselves. Building a fragrance or flavour that delights consumers and also survives the product's chemistry needs three things a brand owner does not want to own:

• a library of thousands of raw materials, including proprietary "captive" molecules nobody else can use;
• a bench of trained perfumers and flavourists, a craft taking roughly a decade to learn;
• consumer-research data showing which scents and tastes win in which country.

A detergent's perfume must survive a hot, alkaline wash. A beverage flavour must stay stable on a sunny shelf for a year. A sugar-reduced yoghurt must not taste of the stevia used to cut the sugar. Givaudan sells the answer to such briefs, protected as a trade secret, and gets paid every time the product is made.

What makes it hard. The formula itself is cheap to mix and nearly impossible to reproduce exactly. Its value sits in creative skill and accumulated data, and in qualification: once a formula is inside a product, changing it means re-testing the product. Section 3 covers how this works in practice.

A worked example. A global household-care company plans a new premium laundry detergent for Brazil and India and issues a "brief" to the fragrance houses on its approved supplier list. The brief sets a scent direction, a target cost per kilogram of fragrance oil, the detergent base it must survive and the consumer moments that matter: smell in the bottle, in the wash, on wet laundry and on dry clothes days later. Givaudan's perfumers in its Latin American and Asian creative centres build candidate formulas. They lean on in-house consumer data about what "clean" means in each market and on encapsulation technology that releases scent when fabric is rubbed. Candidates go through stability tests and the customer's consumer panels. If Givaudan wins, it does not get a fixed contract. It becomes the sole source of that fragrance oil and compounds it in a plant near the customer's factory, for example its Mexican or Indian sites. It earns revenue for as long as the detergent sells, often many years, and the formula stays Givaudan's property.

Andrier summed up how the company wants to be judged when he presented the FY2025 results:

"CAGR is your best friend when judging Givaudan's performance." - Gilles Andrier, FY2025 results call, January 2026

2. Business Segments

Givaudan reports two divisions of almost equal size. In 2025 Fragrance & Beauty had sales of CHF 3,830 million (51% of the group) and Taste & Wellbeing CHF 3,642 million (49%). The mix is shifting towards Fragrance & Beauty: it was about 53% of sales in H1 2026 because fragrance grew faster and Taste & Wellbeing stalled.

2.1 Fragrance & Beauty (51%)

What it does. This division sells three things, which it reports as separate business units:

• Consumer Products. About 60% of the division (H1 2026 call). It sells fragrance oils for laundry detergents, fabric softeners, shampoos, soaps, deodorants, air fresheners and household cleaners. Customers range from the multinational household and personal-care groups to thousands of regional and private-label manufacturers. This is the high-volume, application-engineering side of perfumery: the fragrance has to survive bleach, surfactants and heat, and still perform after the wash.
• Fine Fragrances. It creates perfumes and colognes for luxury fashion houses, prestige beauty groups, celebrity and "niche" brands, and increasingly Middle Eastern and Indian perfume houses. Givaudan says this business doubled in size over the five years to 2025. Fine Fragrance grew 18% like-for-like (LFL) in 2025 on top of a similar rise in 2024, before slowing to 7.3% in H1 2026.
• Fragrance Ingredients & Active Beauty. It manufactures aroma molecules, both commodity and proprietary, and sells some of them to other fragrance houses. It also makes "active" cosmetic ingredients: peptides, botanical extracts, biotech-derived squalane and similar materials that skin-care brands put on the label. This unit is the most volatile because part of it sells to competitors. Management attributed its 2026 decline to that channel, not to end demand (H1 2025 call; Q1 and H1 2026 releases).

Core capability. The division owns a perfumers' school, a palette of captive molecules and the consumer-preference data behind thousands of briefs a year. It also runs the industrial know-how to compound complex formulas reliably at scale in dozens of countries. Its Fine Fragrance perfumers and the creative reputation that comes with them are the hardest asset to replicate (Section 5).

Why it is separate. Perfumery and flavour chemistry share some raw materials, but the customers, creative skills, regulation (cosmetics and IFRA standards against food law) and cost structure differ. Fragrance carries richer economics than most flavour work.

Role in the group. Fragrance & Beauty is the current growth and profit engine. In 2025 it grew 7.9% LFL against 2.4% for Taste & Wellbeing (FY2025 release). Acquisitions under the 2030 strategy are concentrated here: Belle Aire Creations (USA, completed December 2025), Vollmens and the pending Eurofragance deal.

Main rivals: dsm-Firmenich, IFF, Symrise, Mane, Takasago and, in ingredients, a handful of specialty chemical makers (Section 5).

2.2 Taste & Wellbeing (49%)

What it does. This division sells flavours and "taste solutions" across six food and beverage segments: beverages, dairy, savoury, snacks, sweet goods and health and nutrition. It adds two adjacencies built by acquisition, natural colours and health and functional ingredients (botanical extracts and plant-based actives, largely from Naturex). Customers range from global soft-drink, snack and dairy multinationals to regional food makers in Southeast Asia, India, the Middle East and Latin America. Givaudan reports this division by region, not by product.

Core capability. Flavour creation is half of what it sells. The other half is taste modulation: making a reduced-sugar drink taste sweet, hiding the bitterness of plant proteins, giving a meat analogue its savoury, fatty mouthfeel. This is chemistry and sensory science combined with application know-how about how flavours behave in extrusion, frying, baking or retort. That application expertise, and the willingness to co-develop a product with a customer's R&D team, is the moat-relevant part.

Why it is separate. Food regulation, food-grade manufacturing (spray drying, extraction, emulsions), different customers and lower average margins all justify a distinct division. Its history is also different: much of it came from FIS (Nestlé) and Quest, then Naturex and the colour deals.

Role in the group and the current problem. Taste & Wellbeing is the larger cash generator by headcount and plants, but the slower grower. Growth slowed to 2.4% LFL in 2025, turned slightly negative in Q1 2026 and only edged back to +0.5% LFL in H1 2026. At the 27 August 2026 Summer Investor Conference management gave its own diagnosis. Natural colours and health and functional ingredients make up about 14% of the division. Around half of that cluster, roughly CHF 250 million of sales, sits in more commoditised segments, mainly in North America, that weigh on both growth and margin. The 2030 strategy changes this division's mandate from "expand categories and portfolio" to "strengthen core categories and optimise portfolio". The plan has three parts: defend high-share segments, win in fast-growing beverage sub-segments, and "fix underperformers" in health and functional. Section 7 covers what is planned and Section 8 what could go wrong.

Main rivals: dsm-Firmenich, IFF, Symrise, Kerry, Mane, Döhler, Sensient in colours, and many local flavour houses (Section 5).

Summary

Geographic mix

In 2025 Givaudan sold 42% of its products in Europe, Africa and the Middle East (EAME), 24% in Asia Pacific, 23% in North America and 11% in Latin America (company "About Givaudan" facts). It also divides the world into high-growth markets (Asia excluding Japan, Latin America, Central and Eastern Europe, the Middle East and Africa) and mature markets. High-growth markets now provide 49% of sales. That is the result of decades of building creation centres and plants in São Paulo, Mexico, Singapore, Shanghai, Mumbai, Dubai and Jakarta, at a time when competitors served these markets from Europe.

Each region behaves differently:

• South Asia, Middle East and Africa: the fastest Taste & Wellbeing region in 2025 (+7.8% LFL), and the home of a booming local fine-fragrance culture.
• Asia Pacific: slipped in 2025 (Southeast Asian snack and beverage customers) and recovered strongly in H1 2026.
• North America: the weak spot of 2026. Lower-income consumers trading down hurt branded food volumes, and the commoditised colour and functional sales sit there too.
• Latin America: volatile with local economies. Mexico was flagged as a soft spot in the FY2025 call.
• Europe: steady, low growth.

3. Products and Operations

3.1 The product families that matter

Fragrance compounds (the core of Fragrance & Beauty). A fragrance compound is a liquid blend of typically dozens of raw materials, sometimes more than a hundred. They include synthetic aroma molecules, natural essential oils and absolutes (vetiver, patchouli, citrus oils, jasmine) and solvents or fixatives. The formula is a trade secret held by Givaudan, and customers receive only the regulatory data they need.

• Consumer products work is constrained by cost per kilogram and chemistry. The fragrance must stay stable in strongly alkaline or acidic bases, must not discolour the product, and must "perform" at several moments in use. Encapsulation (micro-capsules that burst on friction) and pro-fragrance technologies are a key differentiator because they let a small dose last longer on fabric or skin.
• Fine fragrance work is constrained by creativity and brand fit. A prestige launch is judged by the brand's marketing and evaluation team, and a single winning perfume can sell for decades.

Aroma molecules and captives. Givaudan synthesises many of its own ingredients. A subset are "captives": patented or know-how-protected molecules developed in its Zurich-area research centre and reserved for its own perfumers. Captives make Givaudan formulas both distinctive and harder to copy by reverse engineering with gas chromatography. The non-captive output is sold on the market, including to rivals, which explains the volatility noted in Section 2.1.

Active Beauty. Cosmetic actives such as anti-ageing peptides, plant extracts, and biotech-derived ingredients like the squalane range from the 2023 purchase of Amyris's ingredient portfolio. Skin-care formulators buy these as named, claim-supporting ingredients, a different sale from fragrance, closer to specialty chemicals.

Flavours and taste systems (the core of Taste & Wellbeing). These come in liquid, emulsion and powder form (spray-dried or encapsulated) for six product categories. The technically demanding part is taste modulation, which management calls central to its growth plans:

• sugar reduction for beverages and dairy;
• salt reduction for snacks and savoury;
• masking the beany, bitter or metallic notes of plant proteins, vitamins and high-protein formulations.

Natural colours. These are colours from carrots, beetroot, spirulina, paprika, turmeric, purple sweet potato and caramelised sugar, sold mainly under the Givaudan Sense Colour name and built from the DDW (2021) and b.kolor (2025) acquisitions. The technical difficulty is stability: natural pigments fade in light, shift with pH and react with other ingredients. Making them behave like a synthetic dye in a sports drink or a sweet is formulation work, not commodity extraction.

Health and functional ingredients. These are mainly Naturex botanical extracts: plant actives for supplements, food and nutrition. Some are proprietary and clinically supported. Others are largely commoditised extracts, the part management is now reviewing (Section 2.2).

3.2 How products are made and delivered

The value chain has five steps:

1. Raw material sourcing. Management describes input costs as split roughly evenly between synthetics, which follow petrochemical and specialty chemical prices, and naturals, which follow harvests, weather and geopolitics (H1 2026 call). Givaudan runs sourcing programmes in producing countries, for example for vanilla, vetiver and citrus.
2. Ingredient manufacture. Chemical synthesis of aroma molecules and extraction or fermentation for naturals and actives, in specialised plants in Switzerland, France, Spain, the US, Mexico, India and China.
3. Creation. Perfumers and flavourists in creation centres near customers in Paris, Geneva, New York, Singapore, São Paulo, Dubai and Mumbai design formulas against briefs, increasingly with digital tools. The Summer 2026 conference showcased Optimiser, an AI tool for production sequencing, and OOBY, an AI tool for food-concept development.
4. Compounding. Plants weigh and blend the raw materials to formula in batches, then fill drums, totes or bulk containers. Compounding is not capital-intensive per tonne, but it needs precise automation, quality control and a vast raw material inventory, so it is located near customers to shorten lead times and cut duty and freight.
5. Delivery to the customer's factory, often on a just-in-time basis for large consumer goods plants.

The group has 77 production sites. Net investment runs at about 4-5% of sales and is guided to stay in that range through 2030 (H1 2026 call).

3.3 Recent capacity and plant events

• Louisville, Kentucky explosion (12 November 2024). A batch reactor making caramel colour at the Givaudan Sense Colour plant ruptured after exceeding three times its allowable pressure. Two workers died, 11 were injured, and neighbouring homes and businesses were damaged (US Chemical Safety Board investigation update; local reporting). Givaudan said it would not rebuild on the Payne Street site. In the H1 2025 call management put the related costs at about CHF 9 million per half-year in 2025 and expected full insurance coverage thereafter. The accident is the reason caramel colour capacity in North America had to be re-sourced.
• Pedro Escobedo, Mexico (May 2026). An expanded Fragrance & Beauty ingredients facility became fully operational, and construction started on a greenfield fragrance compounding factory planned to reach 20,000-25,000 tonnes of capacity by 2029. The combined investment exceeds USD 160 million (Givaudan release, 2026).
• Cikarang, Indonesia (July 2026). A new 24,000 m² plant on a 50,000 m² site opened to make savoury, sweet and snack flavour powders for Southeast Asia (company and trade-press reports). Givaudan has also added a Jakarta fragrance creation hub.
• Acquired capacity. Belle Aire Creations (Illinois, completed December 2025) adds US compounding focused on regional customers. Eurofragance (pending) would add plants in Spain, Singapore and Mexico, plus manufacturing partners in China and India.

The capacity pattern is consistent: new compounding and powder plants in high-growth markets, plus acquired regional fragrance houses in mature ones, all aimed at serving local and regional customers faster.

4. Customers

4.1 Two customer universes

Givaudan says 59% of 2025 sales came from local and regional customers and 41% from global customers (company facts). This split matters more than any industry split, because the two groups buy differently.

Global customers are the multinational household, personal-care, beauty, food and beverage groups. Givaudan does not publish customer names. These companies run formal procurement through "core lists": a short list of approved fragrance or flavour suppliers, usually the four majors and sometimes one or two others. Only listed suppliers may answer a brief. Inside the customer:

• Procurement controls who gets on the list and negotiates price frameworks, payment terms and raw material pass-through.
• The brand and R&D teams decide which submission wins a given brief, mainly on consumer-test performance, technical fit and cost-in-use.

A large brief can take months from issue to award, and a launch a year or more. Being on the core list is a prerequisite, and scale, regulatory capability and global supply reliability are what get a supplier listed. Winning briefs then depends on creative hit rate.

Local and regional customers range from a family-owned detergent maker in Nigeria to a Gulf perfume house or a Mexican snack company. They choose suppliers on responsiveness, small minimum orders, creative help and local service. The decision-maker is often the owner or a small technical team, and cycles can be weeks. These customers have been Givaudan's faster-growing pool for years, and the 2030 strategy, the Belle Aire and Vollmens deals and the Eurofragance acquisition all target them more deliberately. The "continued outperformance of local and regional customers" was a recurring explanation for growth in 2025 (9M 2025 release).

Fine fragrance customers form a third group. Luxury fashion houses, prestige beauty conglomerates, niche brands and the fast-growing Middle Eastern and Indian perfume houses brief several houses for a new perfume. The decision rests with the brand's creative and evaluation team, and the relationship between a brand and a named perfumer can carry across launches.

4.2 Why customers choose Givaudan

• Creative hit rate and breadth of palette. Captive molecules and a large perfumer bench increase the chance of winning a brief.
• Consumer insight. Givaudan holds proprietary sensory and consumer-preference data across many countries, so it can tell a customer what "clean" or "refreshing" means in Lagos as well as Lyon.
• Taste modulation know-how, for reformulation projects driven by sugar taxes, health regulation, protein trends and GLP-1 diets (Section 7).
• Global reliability. It can supply the same formula from several continents with identical regulatory documentation.
• Local presence in high-growth markets, with creative and manufacturing teams in the country, not a sales office.

4.3 Switching costs

Switching costs are the core of the business model, and they are higher than the contract structure suggests.

• The formula belongs to Givaudan. A customer who wants to move a fragrance or flavour must ask another house to recreate it. That is possible with analytical chemistry, but captives make exact matches hard, and any change must pass consumer testing to show loyal buyers notice no difference.
• Requalification. A new supplier's version must pass stability, safety and regulatory reviews. In food that includes allergen and labelling checks; in cosmetics, IFRA and allergen-labelling compliance.
• Brand risk outweighs savings. Fragrance or flavour is a small share of product cost but a large share of why consumers repurchase. Few brand managers will risk a best-selling product's identity to save a fraction of a percent of cost of goods.

Switching therefore happens mostly at relaunch or renovation, when a product is reformulated anyway and the brief goes back out. This makes Givaudan's revenue sticky on the existing portfolio but contestable on new launches. Win rates on new briefs determine market share over time.

4.4 Concentration

Givaudan does not publish customer-concentration figures. The 41% share of global customers is the best proxy for exposure to the large multinationals. Within that group a few household and personal-care giants are known industry-wide to be very large buyers of fragrance. Their purchasing power shows up in price negotiations and payment terms, not in sudden losses of business, because revenue is spread across thousands of separate formulas. Section 8 covers the receivables build in H1 2026, which touches on payment terms.

4.5 Contract structure and predictability

There are generally no long-term take-or-pay contracts. Givaudan is sole supplier of a formula for the life of the product, and volumes follow the customer's sales. That makes revenue recurring in practice, but:

• Volumes move with consumer demand and customer inventory. The 2023 industry-wide destocking showed that customers can cut orders sharply after building safety stock.
• Prices are renegotiated to reflect raw material, currency and, recently, tariff costs, through collaborative price increases with a lag. Management said contracted pricing gives visibility for H2 2026 (H1 2026 call).
• Pipeline is the leading indicator. Management repeatedly cites its brief "win rate" and new-business pipeline, for instance in functional beverages, high-protein foods and natural colours, as the source of next year's growth.

The result is a business with high revenue persistence, modest price leverage, and growth that depends on continued wins in new launches and on a steady stream of customer reformulation.

5. Competitive Landscape and Moat

5.1 Industry structure

Flavours and fragrances is an oligopoly at the top and fragmented below. Four groups, Givaudan, dsm-Firmenich, IFF and Symrise, are estimated to hold 55-60% of the global market. Givaudan describes itself as the global industry leader and is usually put at about a quarter of the market (Verified Market Research industry estimate; company "About" page). Below them sit a few mid-sized family or listed houses (Mane, Takasago, Robertet, T. Hasegawa) and thousands of local houses serving regional customers.

The structure follows from economics:

• Core-list access requires global plants, regulatory capability and a large creative bench, which favours the majors in multinational business.
• Local and regional business has low barriers to basic compounding, so small houses survive on service and price.

The majors' strategy has been to buy those small houses, which is exactly what Givaudan's recent acquisitions do.

5.2 The competitors

5.3 How Givaudan wins and loses

Against dsm-Firmenich. This is the most direct contest. Firmenich, a Geneva neighbour, matches Givaudan in fine fragrance creativity and ingredient chemistry. Givaudan has a structural edge while dsm-Firmenich is digesting a large merger, separating its animal nutrition business and integrating cultures. A merged rival focused on its own reorganisation tends to cede briefs. Givaudan's double-digit Fine Fragrance growth through 2024-2025 is consistent with gaining share during that period, though it does not prove it.

Against IFF. IFF has been weighed down by high leverage after the Frutarom and DuPont Nutrition & Biosciences acquisitions, and it has spent several years selling businesses. Givaudan has gained from a rival that had less capacity to invest in creation and service. In flavours IFF remains formidable, with a broad food-ingredients offer.

Against Symrise. Symrise's strength is backward integration into aroma chemicals and a pet-food business Givaudan lacks. In Fine Fragrance and high-growth markets Givaudan has more scale. In 2026 the two are running at similar low-to-mid single-digit organic growth.

Against Kerry, Döhler and Sensient (Taste & Wellbeing). Kerry and Döhler sell complete taste and ingredient systems, which appeals to food makers wanting one supplier for the flavour, the base and the functional ingredients. Givaudan wins on flavour creation and modulation depth. It can lose where customers prize a full recipe solution, which is why management now talks of "increasing share in product value and recipes" (Summer 2026 conference). In natural colours, Sensient is a focused rival. Givaudan's argument is that taste-masking and colour together make reformulation away from synthetic dyes easier (H1 2026 call).

Against local houses. Small regional houses win on speed and price. Givaudan's answer has been to buy several of them and set up dedicated local teams.

5.4 Barriers to entry

• Core-list qualification for multinationals requires global supply, regulatory dossiers in many jurisdictions and proven reliability. A new entrant cannot get listed quickly.
• Creative talent takes years to train. Senior perfumers are a small, mobile population, and the majors run their own schools.
• Raw-material palettes and captives, built over decades of R&D, and consumer databases accumulated from thousands of briefs.
• The installed base. Revenue rests on existing formulas, so a newcomer must win new briefs one at a time while incumbents keep theirs.

These barriers are high for the multinational and fine fragrance business and moderate for regional commodity compounding.

5.5 Structural shifts

• Consolidation continues. The Firmenich-DSM merger (2023), IFF's portfolio pruning and Givaudan's steady acquisition of regional houses mean fewer, larger players at the top.
• Regional brand growth in Asia, the Middle East, Africa and Latin America favours suppliers with local presence, Givaudan's long-standing strategy.
• AI-assisted creation could compress the time to answer a brief and could, in theory, lower the barrier for smaller houses. In practice, the data needed to train such tools (formula libraries, consumer-test results) sits with the majors.
• Competition-law scrutiny of the four majors for alleged price coordination (Section 8.1) could, in the extreme, change how the industry prices.

Moat: Wide - switching costs, intangible assets (formulas, captive molecules, creative talent, consumer data), regulatory and qualification barriers

The evidence is structural and has been tested. Formulas belong to the supplier and must be requalified to switch (Section 4.3). Core-list access limits which suppliers can bid for multinational briefs (Section 5.4). Givaudan's share held and grew through the 2008-09 crisis, the 2022-23 raw-material inflation and destocking cycle, and well-funded consolidation by dsm-Firmenich and IFF. The moat is narrower in Taste & Wellbeing's commoditised colour and functional ingredients, where management concedes it has struggled (Section 2.2). The single thing most likely to erode it is regulatory: a competition-authority finding that forces the industry to change its pricing practices, or an investigation outcome that damages the core-list relationship with major customers.

6. Industry

6.1 What drives demand

Flavour and fragrance demand follows the volume of packaged consumer goods sold, plus how much those goods are reformulated. That gives the industry two growth engines.

Volume grows with population, income and urbanisation. A household that moves from bar soap to liquid detergent, softener and shower gel multiplies its fragrance consumption. The same is true of a consumer who shifts from home cooking to packaged snacks and drinks. This is why high-growth markets, which still consume far less fragranced and flavoured products per head than Europe or the US, have grown faster for decades.

Reformulation and new launches drive growth independent of volume. Brands constantly renovate products to gain shelf excitement. Health policy forces reformulation through sugar taxes, salt targets, front-of-pack labelling and bans on certain additives. Each change means a new brief.

Fine fragrance adds a discretionary, fashion-driven element. The post-pandemic years brought an unusual prestige-fragrance boom, driven by younger consumers, layering trends and the spread of a perfume culture in the Middle East and India. Prestige growth slowed in 2026.

6.2 Size and growth

Estimates of the global flavours and fragrances market vary with definitions. Several market-research firms put it at roughly USD 34-43 billion in 2025 (Grand View Research, IMARC, Market Research Future), with long-run growth in the mid-single digits. Givaudan's own "expanded market" adds functional ingredients, colours and cosmetic actives. Its 2030 target of 4-6% average annual organic growth implies it expects to grow at or slightly above the market.

6.3 Place in the supply chain

The industry sits between raw-material suppliers (petrochemical and specialty chemical producers, essential-oil farmers and distillers, extraction companies) and consumer-goods brand owners. It is a small, high-value link: the concentrate is a minor share of the finished product's cost, but it carries a disproportionate share of the consumer's sensory experience. That position gives the majors pricing power over raw-material pass-through and makes them resilient to downstream volume swings, because brand owners rarely cut fragrance or flavour quality first.

6.4 Regulation

• Fragrances are governed by industry standards set by IFRA (International Fragrance Association), which restricts or bans ingredients for safety, and by national cosmetics law. The EU's 2023 expansion of the list of fragrance allergens that must appear on labels forces reformulation and relabelling over a multi-year transition.
• Chemicals fall under EU REACH and equivalent regimes, which raise the cost of keeping molecules on the market and favour suppliers with large regulatory teams.
• Food is governed by food-safety and labelling law. A US policy move away from petroleum-based synthetic dyes, announced by US health authorities in 2025 and referred to by management as "MA" regulation (likely the MAHA, Make America Healthy Again, initiative), is pushing food makers towards natural colours (H1 2026 call). Sugar taxes in many countries drive sugar-reduction work.
• Competition law has become a sector-wide factor. EU, UK, Swiss and US authorities opened coordinated investigations into the four majors in 2023. The US Department of Justice closed its probe in February 2026 without charges, but the European investigation continued (MLex, IFF 10-Q 2026).

6.5 Cyclicality

The industry is defensive. Most volume goes into everyday consumer staples such as detergent, toothpaste, snacks and soft drinks, which hold up in recessions. The cyclical elements are:

• Customer inventory swings. Brand owners build safety stock when supply is tight and run it down when it eases, as in the 2023 destocking.
• Fine fragrance, which is discretionary.
• Raw-material inflation, which squeezes margins until price increases catch up, usually with a lag of a few quarters.

6.6 Tailwinds and headwinds

Tailwinds

• Rising consumption per head in high-growth markets.
• Health-driven reformulation: sugar, salt and fat reduction, high-protein products.
• The regulatory shift from synthetic to natural colours.
• Growth of regional brands, especially in fine fragrance in the Gulf and India.
• The spread of GLP-1 weight-loss drugs, which management argues creates demand for protein-masking and nutrient-dense formats.

Headwinds

• Weak lower-income consumer demand in North America and some emerging markets.
• GLP-1 drugs may also reduce total calories consumed and snack volumes.
• Normalisation of the post-pandemic fragrance boom.
• Tariff and trade volatility.
• Rising regulatory cost and competition-law scrutiny.

7. Growth Triggers

Listed in order of how much each could change the business:

• Eurofragance majority stake, pending regulatory approval. Givaudan agreed on 5 June 2026 to buy a majority of the Barcelona-based fine and consumer fragrance house, which would add plants in Spain, Singapore and Mexico and a customer base concentrated in high-growth markets. Management framed it as part of a continuing acquisition programme, telling investors that M&A, not buybacks, is the near-term priority for capital (Eurofragance announcement, 5 June 2026; H1 2026 call, 23 July 2026; Summer Investor Conference, 27 August 2026).

• Taste & Wellbeing portfolio reset. Under the 2030 strategy's "Optimise" pillar, management will strengthen core flavour and taste solutions, accelerate natural colours and refine the health and functional portfolio to "fix underperformers". This could include exiting or restructuring the commoditised sales identified in Section 2.2, mostly in North America. Management also targets fast-growing beverage sub-segments: functional drinks, low- and no-sugar, and low- and no-alcohol (Summer Investor Conference, 27 August 2026). The H1 2026 call promised continued sequential improvement in the division through H2 2026, and that expectation has been repeated since the Q1 2026 release.

• Natural colours conversion in the US. Management reports strong pipeline momentum as US food makers move away from synthetic dyes. It argues that combining colour with its taste-masking technology differentiates it from pure colour suppliers (H1 2026 call, 23 July 2026; reinforced at the Summer Investor Conference).

• GLP-1, protein and sugar reduction. Stammkoetter told analysts GLP-1 drugs are a net positive for Givaudan because they create demand for protein masking, sugar reduction and nutrient-dense, smaller-portion formats, areas where the company has technical depth (H1 2026 call, 23 July 2026).

• Pedro Escobedo greenfield compounding factory, Mexico. Construction started in 2026 on a plant designed to reach 20,000-25,000 tonnes by 2029, serving Latin American fragrance customers alongside the expanded ingredients facility (Pedro Escobedo groundbreaking release, May 2026; H1 2026 call).

• Cikarang flavour powder plant, Indonesia. Opened in July 2026 to supply savoury, sweet and snack flavours to Southeast Asian food makers, a region where Asia Pacific Taste & Wellbeing growth has resumed (H1 2026 call, 23 July 2026; company release, July 2026).

• Local and regional customer push in North America. Integration of Belle Aire Creations (completed December 2025) and Vollmens gives Fragrance & Beauty a dedicated platform for regional US brands (Q1 2026 release; H1 2026 release, 23 July 2026).

• Data, digital and AI as creation and operations tools. These are the "Future-proof" pillar, including AI production sequencing (Optimiser) and AI-assisted food concept development (OOBY) (Summer Investor Conference, 27 August 2026).

8. Key Risks

8.1 Competition-authority investigations and civil claims

Mechanism. Since 2023 the European Commission, the UK CMA and Swiss COMCO have investigated the four fragrance majors for allegedly coordinating price increases, allocating markets and limiting supply. The US DOJ closed its probe in February 2026 without charges. Indian reports also describe a Competition Commission inquiry into alleged anti-poaching arrangements. In parallel, US end-user and purchaser class actions continue against Givaudan, dsm-Firmenich and Symrise after IFF settled its share. Givaudan booked litigation settlements and provisions of CHF 83 million in H1 2026. It described them as "an agreement reached in connection with the broader competition authorities' investigations into the fragrance industry", without naming the counterparty publicly (H1 2026 release).

How it would hurt. EU cartel fines can reach 10% of global turnover, although actual fines are usually far lower and leniency or settlement discounts are common. A formal finding would expose Givaudan to follow-on damages claims in Europe. A finding that pricing was coordinated could also reset how customers negotiate pass-through, the issue that matters most for the business.

Calibration. A medium-probability, moderate-to-severe risk. The H1 2026 settlement shows the matter has financial consequences. The DOJ closure lowers the US tail, and European timing is unknown.

8.2 Taste & Wellbeing stagnation

Mechanism. The division covered in Section 2.2 slowed from solid growth to near zero in a year. Three forces are at work: North American consumers trading down, weak Latin American demand, and a commoditised colour and functional tail. If the reset in Section 7 fails, the division drags group growth below the 4-6% target, because Fragrance & Beauty would have to carry the whole group at high single digits.

GLP-1 cuts both ways. Management is upbeat:

"For me, GLP-1 is positive." - Christian Stammkoetter, H1 2026 call, 23 July 2026

The mechanism behind his optimism is real: protein masking and reformulation. The opposite mechanism, fewer snacks and fewer sweet drinks consumed, hits the same division's volumes.

Calibration. A high-probability, moderate drag. Exiting the commoditised tail would itself take a little off reported growth while improving quality.

8.3 Fine Fragrance normalisation

Mechanism. Fine Fragrance roughly doubled in five years and was the single largest contributor to 2021-2025 outperformance (Section 2.1). Growth slowed sharply in H1 2026 against huge comparables. If the prestige fragrance boom fades more decisively, as fashion-driven categories do, Fragrance & Beauty loses its fastest engine just as Taste & Wellbeing is weak. Management warned throughout 2025 that double-digit growth on double-digit comparables could not last, and it has now begun to slow.

Calibration. A medium-probability, moderate risk. The Eurofragance deal partly hedges it by adding high-growth-market fine fragrance volume.

8.4 Cash conversion and rising leverage

Mechanism. Adjusted free cash flow was negative in H1 2026. Receivables rose sharply even though reported sales were flat, and leverage rose from the end of 2025 before the Eurofragance purchase closes. Barclays pressed on whether customers were stocking up or paying slower. CFO Stewart Harris answered:

"We don't see anything other than strong recurring demand and no evidence of any stocking that we would expect to unwind." - Stewart Harris, CFO, H1 2026 call, 23 July 2026

Management promised a "meaningful improvement" in working capital by year-end. If that does not arrive, three explanations remain: big customers have stretched payment terms (a quiet transfer of value from supplier to customer), receivables include pass-through effects, or demand was pulled forward. Each would weaken the 2030 cash target, which is one of the two headline promises, and limit the capacity for acquisitions or dividend growth.

Calibration. A medium-probability, moderate risk, testable at the January 2027 full-year results.

8.5 Leadership transition and the CEO-chair relationship

Mechanism. Stammkoetter is the first outsider CEO in decades, arriving from food and beverage at Danone (biography in Section 10), while the former CEO now chairs the board. The arrangement offers continuity. It also risks blurred lines: a new CEO trying to "fine-tune" the strategy his chairman built, or departures among senior creative staff who identify with the previous regime. The strategy pivot in Taste & Wellbeing is the first test.

Calibration. A low-to-medium probability, moderate risk. No evidence of friction has surfaced.

8.6 Operational safety and raw-material shocks

Mechanism. The Louisville explosion (Section 3.3) showed that a chemical-processing incident can kill people, destroy capacity and create long-tail liability. Separately, half the raw-material bill is natural materials exposed to weather, crop failures and conflict: vanilla, citrus, vetiver, patchouli, guar. Management said it expects low-single-digit input cost inflation in H2 2026 and no El Niño effect this year (H1 2026 call). A sharp input-cost spike would squeeze margins for several quarters before price increases catch up, as in 2022-23. Tariffs add a further layer: Givaudan passed tariff costs to customers in 2025 and is now passing refunds back (Section 9).

Calibration. For a large accident, a low-probability, high-severity risk. For input-cost spikes, a medium-probability, moderate risk.

9. Walk the Talk

The six results events used:

1. Q1 2025 sales release, April 2025
2. H1 2025 results and call, 22 July 2025
3. 9M 2025 sales release, October 2025
4. FY2025 results and call, 29 January 2026
5. Q1 2026 sales release, April 2026
6. H1 2026 results and call, 23 July 2026 (77 days before this report)

The record on 2021-2025. This was the cleanest test, because it was a five-year promise made before COVID's aftermath, the 2022 inflation shock, the 2023 destocking and the competition investigation. Management beat its own growth target by a wide margin and met its cash target. Andrier's "CAGR is your best friend" line (Section 1) was a request to be judged over the cycle, and the cycle judged him well.

Fine Fragrance: an honest warning, repeatedly wrong, then right. Through 2025 management kept warning that Fine Fragrance growth would normalise. The H1 2025 call summary recorded that management "continuously said that they shouldn't expect fine to continue to grow double digit on top of a double digit" while admitting they "like to be proven wrong again". They were proven wrong for all of 2025 and right in 2026. This is the pattern of a management team that under-promises on the volatile parts of the portfolio, a useful bias when reading its current caution on Taste & Wellbeing.

Pricing discipline. Givaudan's language on pricing was unusually firm for a supplier to the world's toughest procurement departments:

"implementing price increases in collaboration with its customers to fully compensate for the increases in input costs" - Q1 2025 sales release, April 2025

It followed through, and when tariffs reversed it returned the refunds, consistent with its stated line that "pricing is not a growth strategy" (H1 2025 call). That consistency matters for the competition investigations in Section 8.1, where pass-through behaviour is the subject.

Asia Pacific: where optimism ran ahead. In July 2025 management expected a positive trend in Asia Pacific Taste & Wellbeing in the second half. It did not come; the region ended 2025 slightly negative. The recovery came in H1 2026, a year late. It is the one material call in the six periods where management was too optimistic on timing, though right on direction.

The new CEO's first promise. At his first results call Stammkoetter recommitted to the inherited targets:

"committed to our 2030 performance ambitions, delivering 4%-6% like-for-like sales growth and Adjusted Free Cash Flow margin above 12% on average over the five-year period from 2026 to 2030." - Christian Stammkoetter, H1 2026 call, 23 July 2026

The start is mixed. Group growth in H1 2026 is below the bottom of the range, and cash flow was negative in the half. Both have seasonal and comparable-base explanations, and management has promised a better second half.

Assessment. On the record of the 2021-2025 cycle and the last six reporting events, this management does what it says on the big commitments, and tends to be conservative on the parts of the business it does not control, such as fashion-driven fine fragrance. Its misses are about timing, not direction. The new CEO has not yet been tested on a full-year commitment: the working capital promise and the Taste & Wellbeing recovery due by January 2027 are the first real checkpoints.

10. Ownership, Governance and Shareholder Friendliness

Part 1: Ownership and control

Givaudan has one class of registered shares, par value CHF 10, one vote per share and equal dividend rights. It has no controlling shareholder. At 31 December 2025, holders above 3% were:

Source: Givaudan significant shareholders page, 31 December 2025.

About 50,918 registered shareholders held 56% of the capital, and the rest sat with unregistered or nominee holders. For a minority shareholder, the structure is plain: no dual-class shares, no golden share and no pyramid. The largest holder has about one-eighth of the votes, not enough to block a special resolution alone. Free float is large.

Part 2: Governance

The notable feature is the chair. Gilles Andrier, CEO for 20 years until 1 March 2026, was elected Chairman at the AGM on 19 March 2026, replacing Calvin Grieder after his 12 years in the role (2026 AGM release). Under common Swiss and international governance codes, a former CEO moving straight to the chair is not considered independent. It concentrates oversight of a new CEO in the hands of the person who built the strategy that CEO inherited (Section 8.5). The rest of the board is non-executive: Victor Balli, Louie D'Amico, Ingrid Deltenre, Sophie Gasperment, Roberto Guidetti and Melanie Maas-Brunner were re-elected, and Ester Baiget Arnau joined. Directors stand for re-election annually.

KPMG was re-elected as auditor, and no audit qualification was found in the material reviewed. Shareholders backed pay with clear but not overwhelming majorities: the consultative vote on the compensation report passed with 92.59%, and the maximum for Executive Committee fixed and long-term pay for 2026 with 89.84% (2026 AGM release). No related-party transactions with major holders or management were identified.

Christian Stammkoetter's background, per the company's Executive Committee page: German, born 1971, Diplom-Kaufmann from the University of Münster. He began at Unilever Germany in 1997, held roles at Wella and Procter & Gamble, and became Marketing Director Germany at Numico in 2004. He stayed with Danone after it acquired Numico in 2007, in general management roles. From April 2022 to February 2026 he was President of Danone's Asia, Middle East and Africa zone and a member of its Executive Committee.

Part 3: Capital returns

Dividends. The dividend per share rose each year: CHF 68 for FY2023, CHF 70 for FY2024 and CHF 72 for FY2025, paid in 2024, 2025 and 2026. Each step was about 2-3%. The FY2025 dividend was the 25th consecutive increase since the 2000 listing (2025 full-year release; 2026 AGM release).

Buybacks and dilution. Givaudan has not repurchased shares in any of the last three years. Its last buyback programmes ran in 2002-2004 (company releases). MoatMap's database shows no buybacks in the ~90 days since 10 July 2026. Issued share capital has stayed at 9,233,586 shares over the period, so the share count is flat. Treasury shares are held to settle share-based pay, not to shrink the count. At the 27 August 2026 Summer Investor Conference management said buybacks were unlikely in the very short term, with acquisitions such as Eurofragance the priority.

Verdict: Returns Capital. A dividend raised every year for a quarter century returns a steady stream of cash, but no buybacks and a rising acquisition budget mean any surplus cash goes to growth rather than back to shareholders.

11. Insider Activities

There was one insider transaction in the last 12 months. It was not material. On 16 April 2026 a person closely associated with a non-executive member of the board sold 17 shares at CHF 2,890, about CHF 49,000 in total (SIX management transaction, 2026-04-16; MoatMap database). The filing does not name the person, so their identity is not given here. MoatMap tags the filer as a substantial shareholder (SSH), but under Swiss rules the disclosure was a management transaction for a related person, not a 5% holder. The sale is trivial relative to the company's size and to typical board holdings. No reason was disclosed. No director or executive bought shares on the open market. A secondary aggregator also lists a matched purchase and sale of 130 shares by an executive officer on 12 December 2025, which looks like a plan settlement, but it could not be verified against the SIX register. The SIX Exchange Regulation database could not be queried directly for the most recent two weeks, so filings after the MoatMap scrape may be missing. Read: neutral. Insider activity is minimal and carries no signal either way.

12. Scenarios

Bull case. Fragrance & Beauty settles into steady high-single-digit growth. Fine Fragrance normalises at a healthy pace instead of reversing, and Consumer Products keeps winning local and regional customers. Eurofragance closes and slots into high-growth markets as Belle Aire did in North America. The Taste & Wellbeing reset works: the commoditised North American tail is restructured or exited, natural colours and taste-masking win reformulation briefs as US synthetic dyes are phased out, and GLP-1-driven demand for protein and smaller formats turns into new business. The European investigation ends with a settlement the market can absorb. Working capital normalises by year-end, the 2030 cash target looks credible, and the Stammkoetter-Andrier pairing reads as a smooth handover. By 2028-29 Givaudan looks like a cleaner, more focused company growing at the top of its range, with the Taste division's quality matching its fragrance side.

Base case. Management delivers roughly what it has guided. Fragrance & Beauty carries the group while Fine Fragrance slows to a sustainable mid-to-high single-digit pace. Taste & Wellbeing improves gradually from its 2026 low, helped by Asian growth, the Indonesian and Mexican plants and the colour pipeline, but it remains the slower half for several years. The portfolio clean-up shaves a little from growth before it helps. Group growth sits in the lower half of the 4-6% range at first and drifts up as acquisitions and new plants contribute. Cash conversion recovers in 2027. The competition matter produces further settlements but no structural change to pricing. On the evidence of Section 9, the most likely outcome is a management team that hits the long-run targets roughly on average, with timing slippage in individual regions.

Bear case. Risks 8.2 and 8.3 compound. North American and Latin American food demand stays weak, GLP-1 adoption cuts snack and sweet-drink volumes faster than it creates protein and reformulation business, and Fine Fragrance falls from boom to outright decline as the prestige cycle turns. Group growth drops below the 2030 range for more than a year. 8.4 follows: working capital does not improve because large customers have stretched payment terms. With leverage already rising and Eurofragance to pay for, the company slows acquisitions just when it needs them. 8.1 turns from a provision into a fine plus follow-on claims, and customers use the episode to press for harder pricing terms. Under that pressure 8.5 surfaces: the new CEO's portfolio changes and the chairman's legacy strategy pull in different directions, and senior creative talent leaves. The moat holds, but the business looks like a slower, lower-quality version of the one that beat its last five-year plan.